Phospholipase A This knowledge was used in the recursive development of later generation inhibitors based on structurally distinct chemotypes that showed improved safety, metabolic stability, and pharmacokinetic profiles while retaining or improving upon the affinity and selectivity for p38 MAPK [36-38] tuskonus November 4, 2022